Payment overview · 2025
General Payments
$1,281.64
55 reported records · 18 companies
Healthcare provider profile · identity verified
Dashi Bao, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1821353970
Verified facts
What the public records show
CMS Open Payments records show Dashi Bao, M.D. received $1,281.64 in general payments during 2025 across 55 reported records.
Gilead Sciences, Inc. accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Prolia, Rybelsus, Shingrix, Vemlidy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $349.62 | 27.3% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $287.07 | 22.4% | 13 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $80.00 | 6.2% | 5 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.86 | 6.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.67 | 4.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.45 | 4.2% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $49.16 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.93 | 3.6% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.32 | 3.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.41 | 2.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.10 | 2.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.30 | 2.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.11 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.29 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.10 | 1.7% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $21.13 | 1.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.57 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.55 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,281.64 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $147.47 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $139.60 | 7 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $80.00 | 5 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $77.86 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.67 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $49.16 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $44.32 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.41 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.41 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 106 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 121 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 156 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 24 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 60 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 39 | exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
121 | 41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
104 | 38 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
39 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
60 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1207 | 428 |
| Losartan Potassium | Losartan Potassium | 823 | 278 |
| Donepezil Hcl | Donepezil Hcl | 753 | 245 |
| Amlodipine Besylate | Amlodipine Besylate | 626 | 232 |
| Metformin Hcl | Metformin Hcl | 533 | 170 |
| Metoprolol Succinate | Metoprolol Succinate | 488 | 149 |
| Tamsulosin Hcl | Tamsulosin Hcl | 428 | 153 |
| Alendronate Sodium | Alendronate Sodium | 416 | 135 |
| Finasteride | Finasteride | 298 | 96 |
| Diclofenac Epolamine | Diclofenac Epolamine | 252 | 120 |
| Azithromycin | Azithromycin | 226 | 188 |
| Trazodone Hcl | Trazodone Hcl | 219 | 124 |
| Naproxen | Naproxen | 205 | 172 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 66 |
| Famotidine | Famotidine | 179 | 109 |
| Simvastatin | Simvastatin | 177 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 61 |
| Glipizide Er | Glipizide | 163 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 91 |
| Vascepa | Icosapent Ethyl | 157 | 58 |
| Jardiance | Empagliflozin | 156 | 53 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 152 | 49 |
| Carvedilol | Carvedilol | 148 | 42 |
| Omeprazole | Omeprazole | 144 | 117 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 98 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 130 | 99 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 129 | 111 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 127 | 68 |
| Gabapentin | Gabapentin | 125 | 83 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 59 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 124 | 43 |
| Farxiga | Dapagliflozin Propanediol | 121 | 41 |
| Azelastine Hcl | Azelastine Hcl | 119 | 95 |
| Eliquis | Apixaban | 106 | 30 |
| Synjardy | Empagliflozin/Metformin Hcl | 104 | 38 |
| Meclizine Hcl | Meclizine Hcl | 102 | 82 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 33 |
| Fenofibrate | Fenofibrate,micronized | 100 | 27 |
| Xarelto | Rivaroxaban | 95 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 69 |
| Tradjenta | Linagliptin | 83 | 27 |
| Allopurinol | Allopurinol | 81 | 28 |
| Nitroglycerin | Nitroglycerin | 80 | 63 |
| Ammonium Lactate | Ammonium Lactate | 78 | 64 |
| Montelukast Sodium | Montelukast Sodium | 76 | 42 |
| Celecoxib | Celecoxib | 73 | 53 |
| Memantine Hcl | Memantine Hcl | 73 | 29 |
| Vemlidy | Tenofovir Alafenamide | 73 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 71 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 45 |
| Sertraline Hcl | Sertraline Hcl | 64 | 26 |
| Mirtazapine | Mirtazapine | 62 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 25 |
| Ozempic | Semaglutide | 61 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 61 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 17 |
| Rybelsus | Semaglutide | 60 | 22 |
| Telmisartan | Telmisartan | 60 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 44 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 43 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 23 |
| Hydrocortisone | Hydrocortisone | 56 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 54 | 15 |
| Meloxicam | Meloxicam | 54 | 44 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 54 | 18 |
| Amoxicillin | Amoxicillin | 53 | 42 |
| Ibuprofen | Ibuprofen | 53 | 44 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 52 | 40 |
| Glimepiride | Glimepiride | 52 | 21 |
| Loperamide | Loperamide Hcl | 51 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 21 |
| Metronidazole | Metronidazole | 43 | 39 |
| Baclofen | Baclofen | 42 | 30 |
| Ketoconazole | Ketoconazole | 41 | 30 |
| Mupirocin | Mupirocin | 41 | 33 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 39 | 30 |
| Ezetimibe | Ezetimibe | 35 | 18 |
| Jentadueto | Linagliptin/Metformin Hcl | 35 | 11 |
| Ursodiol | Ursodiol | 34 | suppressed |
| Acarbose | Acarbose | 33 | 13 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | 16 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | 18 |
| Mometasone Furoate | Mometasone Furoate | 30 | 28 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 29 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 29 | 12 |
| Folic Acid | Folic Acid | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 23 |
| Icosapent Ethyl | Icosapent Ethyl | 28 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Prednisone | Prednisone | 27 | 19 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Clotrimazole | Clotrimazole | 25 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | 18 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 25 | 14 |
| Procto-Med Hc | Hydrocortisone | 25 | 17 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Prolia | Denosumab | 24 | 22 |
| Methimazole | Methimazole | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Erythromycin | Erythromycin Base | 20 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | 16 |
| Fluocinonide | Fluocinonide | 19 | 18 |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 18 | 18 |
| Furosemide | Furosemide | 18 | 14 |
| Nateglinide | Nateglinide | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 17 | 13 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | 13 |
| Dutasteride | Dutasteride | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Alogliptin | Alogliptin Benzoate | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 13 |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Benzonatate | Benzonatate | 13 | 12 |
| Colchicine | Colchicine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Lisinopril | Lisinopril | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,281.64 · 55 records | Gilead Sciences, Inc. | ABRYSVO, AIRSUPRA, Arikayce, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, JARDIANCE, KISUNLA, Leqembi, MOUNJARO, NURTEC ODT, OPZELURA, Ozempic, PREVNAR 20, PROLIA, PURIFIED CORTROPHIN GEL, PYRUKYND, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA, Vemlidy, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error